Friday, January 27, 2017
Endo International announced that as part of its comprehensive organizational review, it has initiated a restructuring program. These restructuring actions primarily relate to the company’s corporate functions and branded pharmaceutical R&D functions in Malvern, PA, and Chestnut Ridge, NY. The restructuring program will better align these parts of our organization in size and scope with the company’s recently restructured Generics and U.S Branded Pharmaceutical business units. In addition to realizing greater efficiencies, these actions are expected to provide corresponding cost savings. Endo expects to invest a portion of these cost savings in the company’s core product franchises and new product development programs for both the Branded and Generics business segments.